|
GB9105489D0
(en)
*
|
1991-03-15 |
1991-05-01 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9126677D0
(en)
*
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9400411D0
(en)
*
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
KR100447303B1
(ko)
*
|
1994-01-11 |
2005-08-23 |
아노메드 인코포레이티드 |
고리형폴리아민
|
|
US5663161A
(en)
*
|
1995-02-17 |
1997-09-02 |
The Research Foundation Of State University Of New York |
Anti-viral triaza compounds
|
|
US5612478A
(en)
*
|
1995-03-30 |
1997-03-18 |
Johnson Matthey Plc |
Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
|
|
US5606053A
(en)
*
|
1995-05-02 |
1997-02-25 |
Johnson Matthey Plc |
Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
|
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
|
GB9511357D0
(en)
*
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
|
WO1996041020A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Progenics Pharmaceuticals, Inc. |
Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
|
|
EP0955044B1
(de)
*
|
1995-06-26 |
2005-11-16 |
Chelator LLC |
Methode zur Hemmung des Wachstums von Bakterien oder Pilzen mit einem Komplexbildner
|
|
US5608061A
(en)
*
|
1995-08-02 |
1997-03-04 |
Johnson Matthey Plc |
Process for preparing 1,4,8,11-tetraazacyclotetradecane
|
|
US7118859B2
(en)
|
1996-01-17 |
2006-10-10 |
Progenics Pharmaceuticals, Inc. |
Methods for inhibiting HIV-1 infection
|
|
US6344545B1
(en)
|
1996-06-14 |
2002-02-05 |
Progenics Pharmaceuticals, Inc. |
Method for preventing HIV-1 infection of CD4+ cells
|
|
US7858298B1
(en)
|
1996-04-01 |
2010-12-28 |
Progenics Pharmaceuticals Inc. |
Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
|
|
US20040086528A1
(en)
*
|
1996-06-14 |
2004-05-06 |
Progenics Pharmaceuticals, Inc. |
Uses of a chemokine receptor for inhibiting HIV-1 infection
|
|
AU5241099A
(en)
*
|
1998-07-31 |
2000-02-21 |
Trustees Of Columbia University In The City Of New York, The |
Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
|
|
US20040228869A1
(en)
*
|
1998-12-16 |
2004-11-18 |
Progenics Pharmaceuticals, Inc. |
Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
|
|
US20080015348A1
(en)
*
|
1998-12-16 |
2008-01-17 |
Progenics Pharmaceuticals, Inc. |
Nucleic acids encoding polypeptides of anti-CCR5 antibodies
|
|
US6365583B1
(en)
*
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
AP1654A
(en)
*
|
1999-03-24 |
2006-09-01 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds.
|
|
US6750348B1
(en)
|
1999-03-24 |
2004-06-15 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds
|
|
HK1040993B
(en)
|
1999-04-30 |
2006-11-10 |
Cellgate, Inc. |
Polyamines and their use in therapy
|
|
BR0010700A
(pt)
*
|
1999-04-30 |
2002-02-13 |
Slil Biomedical Corp |
Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
|
|
US6649587B1
(en)
|
1999-04-30 |
2003-11-18 |
Slil Biomedical Corporation |
Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
|
|
US6482943B1
(en)
|
1999-04-30 |
2002-11-19 |
Slil Biomedical Corporation |
Quinones as disease therapies
|
|
ATE428706T1
(de)
*
|
1999-12-17 |
2009-05-15 |
Genzyme Corp |
Chemokinrezeptor-bindende heterocyclische verbindungen
|
|
US8271316B2
(en)
*
|
1999-12-17 |
2012-09-18 |
Buzzmetrics Ltd |
Consumer to business data capturing system
|
|
US20030072715A1
(en)
*
|
2000-08-02 |
2003-04-17 |
Benjamin Frydman |
Cyclic polyamine compounds for cancer therapy
|
|
IL154227A0
(en)
*
|
2000-09-15 |
2003-07-31 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
|
US7138119B2
(en)
*
|
2000-09-15 |
2006-11-21 |
Progenics Pharmaceuticals, Inc. |
Compositions and methods for inhibition of HIV-1 infection
|
|
HUP0302960A3
(en)
|
2000-09-15 |
2007-03-28 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
|
|
EP2022787B1
(de)
|
2000-09-29 |
2012-11-28 |
Genzyme Corporation |
Verfahren zur Herstellung von N-1-geschütztem N-Ringstickstoff, der cyclische Polyamine enthält, und entsprechende Produkte
|
|
AU2002235126A1
(en)
*
|
2000-11-08 |
2002-05-21 |
Slil Biomedical Corporation |
Novel polyamine analog-amino acid conjugates useful as anticancer agents
|
|
US7060273B2
(en)
*
|
2001-04-06 |
2006-06-13 |
Progenics Pharmaceuticals, Inc. |
Methods for inhibiting HIV-1 infection
|
|
SI1411918T1
(sl)
*
|
2001-07-31 |
2012-04-30 |
Genzyme Global S A R L |
Postopki za mobilizacijo progenitorskih/matičnih celic
|
|
US7169750B2
(en)
*
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
JP2005511734A
(ja)
*
|
2001-12-07 |
2005-04-28 |
スリル バイオメディカル コーポレイション |
癌治療用のシクロアルキル置換ポリアミンおよびそれらの合成方法
|
|
BRPI0215050B8
(pt)
|
2001-12-21 |
2021-05-25 |
Anormed Inc |
compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem
|
|
US7354932B2
(en)
*
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
US7122185B2
(en)
*
|
2002-02-22 |
2006-10-17 |
Progenics Pharmaceuticals, Inc. |
Anti-CCR5 antibody
|
|
EP1613613B1
(de)
*
|
2003-04-11 |
2021-06-02 |
Genzyme Corporation |
Cxcr4-chemokinrezeptor-bindende verbindungen
|
|
US7501518B2
(en)
*
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
|
EP1615633B1
(de)
*
|
2003-04-22 |
2012-08-15 |
Genzyme Corporation |
Heterocyclische verbindungen, die sich mit verbesserter wirksamkeit an chemokinrezeptoren binden
|
|
US7498346B2
(en)
*
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
|
EP1708703A4
(de)
*
|
2003-12-11 |
2008-04-09 |
Anormed Inc |
Chemokin-rezeptor-bindende verbindungen
|
|
CN101094684A
(zh)
*
|
2004-08-13 |
2007-12-26 |
阿诺麦德股份有限公司 |
用趋化因子的组合活化祖细胞/干细胞
|
|
US7790747B2
(en)
*
|
2005-06-15 |
2010-09-07 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
|
BRPI0614801A2
(pt)
*
|
2005-08-16 |
2009-05-19 |
Genzyme Corp |
compostos de ligação a receptor de quimiocina
|
|
EP1951046B1
(de)
|
2005-08-19 |
2012-07-18 |
Genzyme Corporation |
Verfahren zur verbesserung der chemotherapie
|
|
ES2497092T3
(es)
*
|
2006-02-24 |
2014-09-22 |
Genzyme Corporation |
Procedimientos para el aumento del flujo sanguíneo y/o la estimulación de la regeneración de tejidos
|
|
US20100003224A1
(en)
*
|
2006-08-02 |
2010-01-07 |
Genzyme Corporation |
Combination Therapy
|
|
BRPI0715393A2
(pt)
*
|
2006-08-07 |
2013-06-25 |
Genzyme Corp |
terapia de combinaÇço
|
|
KR20200016407A
(ko)
|
2011-05-16 |
2020-02-14 |
젠자임 코포레이션 |
Cxcr4 길항제의 용도
|
|
AU2016269839B2
(en)
|
2015-06-03 |
2021-07-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
ES2907489T3
(es)
|
2015-12-14 |
2022-04-25 |
X4 Pharmaceuticals Inc |
Métodos para el tratamiento del cáncer
|
|
US11433136B2
(en)
|
2015-12-18 |
2022-09-06 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
ES2935834T3
(es)
|
2015-12-22 |
2023-03-10 |
X4 Pharmaceuticals Inc |
Métodos para tratar enfermedad de inmunodeficiencia
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
WO2019089826A1
(en)
|
2017-10-31 |
2019-05-09 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells
|
|
CN111683669A
(zh)
|
2017-10-31 |
2020-09-18 |
美真达治疗公司 |
用于造血干细胞和祖细胞移植疗法的组合物和方法
|
|
US11260079B2
(en)
|
2017-12-06 |
2022-03-01 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
|
WO2019113375A2
(en)
|
2017-12-06 |
2019-06-13 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
|
WO2019136159A1
(en)
|
2018-01-03 |
2019-07-11 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
|
US20220401481A1
(en)
|
2019-11-01 |
2022-12-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
|
WO2021183650A1
(en)
|
2020-03-10 |
2021-09-16 |
X4 Pharmaceuticals, Inc. |
Methods for treating neutropenia
|
|
AU2021263754A1
(en)
|
2020-04-27 |
2022-12-01 |
Ensoma, Inc. |
Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
|
|
EP4308694A1
(de)
|
2021-03-16 |
2024-01-24 |
Magenta Therapeutics, Inc. |
Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
|
|
WO2025224720A1
(en)
|
2024-04-24 |
2025-10-30 |
Biolinerx Ltd. |
Methods of selecting treatment regimen against solid tumors
|